Filing summary
Registrant identity: The supplied filing is IMARA Inc.’s Form 10-Q, not a filing by Enliven Therapeutics, Inc. It covers the quarter and six months ended June 30, 2020; filed August 14, 2020.
Business context and reporting period
IMARA was a clinical-stage biotechnology company developing IMR-687, an oral PDE9 inhibitor, principally for sickle cell disease (SCD) and beta-thalassemia. It had no approved products and had generated no product revenue. Its development pipeline was concentrated on this sole candidate.
Financial results and liquidity
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | 2020: $7.9m; 2019: $4.4m | 2020: $13.7m; 2019: $7.9m |
| General and administrative expense | 2020: $2.4m; 2019: $1.2m | 2020: $4.0m; 2019: $1.8m |
| Operating loss | 2020: $10.3m; 2019: $5.6m | 2020: $17.7m; 2019: $9.8m |
| Net loss | 2020: $10.2m; 2019: $5.4m | 2020: $17.4m; 2019: $9.6m |
Margins are not meaningful because the company had no revenue. Second-quarter operating expenses rose $4.7m year over year, primarily reflecting higher IMR-687 clinical development and manufacturing costs, increased staffing, and public-company costs. For the six-month period, net loss attributable to common stockholders was $25.3m, including a $7.9m accretion of the Series B preferred stock beneficial conversion feature; this non-cash deemed dividend increased common-stockholder loss, not reported net loss.
At June 30, 2020, cash and cash equivalents were $54.7m, short-term investments $51.6m, and total assets $111.3m. Total liabilities were $5.0m, principally accounts payable and accrued expenses; the filing reports no credit facility or committed capital source. Accumulated deficit was $72.2m.
For the six months, operating cash use was $18.8m (versus $7.6m in 2019); investing cash use was $27.7m, mainly net purchases of short-term investments; and financing provided $96.1m, including IPO and preferred-stock proceeds. Cash, cash equivalents, and restricted cash increased $49.7m to $54.7m. Management estimated available cash, equivalents, and investments would fund operations and capital expenditure requirements into mid-2022, subject to assumptions and risks.
Material changes and financing
- In March 2020, IMARA completed its IPO; together with the underwriters’ April option exercise, it sold 5.405m shares for approximately $76.5m net proceeds. It also raised approximately $17.1m net from a Series B preferred-stock issuance in February.
- At the IPO closing, all outstanding preferred stock converted into 11.173m common shares. Common shares outstanding increased from 702,510 at December 31, 2019 to 17.325m at June 30, 2020. The filing says the IPO proceeds had not been used as of quarter-end.
- Operating expenses and losses increased substantially year over year as clinical activity and headcount expanded and public-company costs rose. The company continued to expect significant losses and negative operating cash flows.
Outlook, commentary, and risks
- Management expected top-line Phase 2a SCD data in Q4 2020 and interim data from the Phase 2b SCD and beta-thalassemia trials in the first half of 2021. The filing cautioned that COVID-19-related site activation, enrollment, and trial-operation disruptions could delay these timelines.
- Management reported preliminary observations from two open-label-extension patients, including fewer reported vaso-occlusive crises and changes in disease biomarkers. It emphasized the very small sample and retrospective comparisons; these observations are not controlled evidence of efficacy.
- The Phase 2b program’s potential use of fetal hemoglobin (HbF) as a surrogate endpoint remained uncertain. The FDA had stressed the need for clear assumptions and robust results; failure to establish clinical benefit could require different endpoints or further studies.
- IMARA began preclinical research into IMR-687 for heart failure with preserved ejection fraction (HFpEF); this was an early research program, not a clinical-stage indication.
- COVID-19 had caused some missed or incomplete Phase 2a visits and delays in Phase 2b site activation, enrollment, and regulatory review. Further effects on trials, suppliers, financing access, and operations remained uncertain.
- The company said existing funds were expected to support operations into mid-2022, but it would need additional funding. Financing might not be available on acceptable terms, and could dilute shareholders, restrict operations, or require licensing or partnering rights.
- Other notable risks included dependence on IMR-687, clinical and regulatory uncertainty, reliance on single-source manufacturers for active ingredient and finished product, competition, and dependence on Lundbeck-licensed intellectual property. Potential Lundbeck milestone payments were up to $23.5m for licensed compounds and up to $11.8m for other PDE9-inhibitor products, plus royalties if products generate sales.
- No material legal proceedings were reported. Management concluded disclosure controls were effective as of June 30, 2020, and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the issuer: this filing is for IMARA Inc., despite the request naming Enliven Therapeutics, Inc.
- Check subsequent clinical-trial disclosures against the stated data timelines, trial enrollment, and COVID-19 delays.
- Assess whether later controlled-trial results support the preliminary two-patient open-label observations and whether the FDA accepts the proposed endpoints.
- Monitor cash burn, investment balances, financing needs, and whether the mid-2022 runway estimate remained achievable.
- Review dilution from outstanding options and equity plans, and the potential effect of future financing or Lundbeck milestone and royalty obligations.